1.4602
price up icon4.30%   0.0602
after-market After Hours: 1.48 0.0198 +1.36%
loading
Galmed Pharmaceuticals Ltd stock is traded at $1.4602, with a volume of 38,836. It is up +4.30% in the last 24 hours and down -35.39% over the past month. Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
See More
Previous Close:
$1.40
Open:
$1.38
24h Volume:
38,836
Relative Volume:
0.05
Market Cap:
$3.18M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-0.4479
EPS:
-3.26
Net Cash Flow:
$-6.14M
1W Performance:
+3.56%
1M Performance:
-35.39%
6M Performance:
-69.64%
1Y Performance:
-66.58%
1-Day Range:
Value
$1.3601
$1.51
1-Week Range:
Value
$1.30
$1.51
52-Week Range:
Value
$1.22
$23.80

Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile

Name
Name
Galmed Pharmaceuticals Ltd
Name
Phone
-
Name
Address
-
Name
Employee
6
Name
Twitter
@GalmedPharma
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
GLMD's Discussions on Twitter

Compare GLMD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GLMD
Galmed Pharmaceuticals Ltd
1.4602 3.18M 0 -6.91M -6.14M -3.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades

Date Action Analyst Rating Change
May-22-20 Downgrade B. Riley FBR Buy → Neutral
Feb-04-20 Initiated Craig Hallum Buy
Jan-30-20 Resumed Cantor Fitzgerald Overweight
Dec-02-19 Initiated Canaccord Genuity Buy
Dec-12-18 Initiated B. Riley FBR Buy
Aug-02-18 Reiterated Maxim Group Buy
Jul-13-18 Initiated Stifel Buy
Jul-12-18 Initiated Cantor Fitzgerald Overweight
Jun-12-18 Reiterated H.C. Wainwright Buy
Mar-15-18 Upgrade Maxim Group Hold → Buy
Feb-14-18 Downgrade Maxim Group Buy → Hold
Feb-12-18 Reiterated H.C. Wainwright Buy
Nov-15-17 Initiated ROTH Capital Buy
Aug-08-17 Reiterated H.C. Wainwright Buy
Jul-31-17 Reiterated Maxim Group Buy
Aug-01-16 Reiterated Maxim Group Buy
Jul-06-16 Resumed ROTH Capital Buy
Mar-28-16 Resumed H.C. Wainwright Buy
Jun-23-15 Initiated H.C. Wainwright Buy
May-06-15 Initiated Sun Trust Rbsn Humphrey Buy
View All

Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News

pulisher
Apr 21, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World

Apr 21, 2025
pulisher
Apr 17, 2025

Galmed partners with VCU to target drug resistance - The Pharma Letter

Apr 17, 2025
pulisher
Apr 17, 2025

Galmed Pharmaceuticals Partners with VCU to Combat Drug Resistance in GI Cancers - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PR Newswire

Apr 17, 2025
pulisher
Apr 15, 2025

Galmed reports key biomarkers for heart and liver health By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Galmed reports key biomarkers for heart and liver health - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Longview News-Journal

Apr 15, 2025
pulisher
Apr 13, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World

Apr 13, 2025
pulisher
Apr 10, 2025

Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PR Newswire

Apr 10, 2025
pulisher
Apr 06, 2025

Maxim Group Reiterates “Hold” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World

Apr 06, 2025
pulisher
Apr 05, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Galmed Phar stock hits 52-week low at $1.32 amid challenges - Investing.com Australia

Apr 04, 2025
pulisher
Apr 04, 2025

Galmed Phar stock hits 52-week low at $1.32 amid challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 02, 2025

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - Yahoo Finance

Apr 02, 2025
pulisher
Mar 28, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Galmed Phar stock hits 52-week low at $1.66 amid challenges - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Galmed Phar stock hits 52-week low at $1.66 amid challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 20, 2025

Galmed Pharmaceuticals Secures New Patent for NASH Therapy - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PR Newswire

Mar 20, 2025
pulisher
Mar 20, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World

Mar 20, 2025
pulisher
Mar 13, 2025

Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World

Mar 12, 2025
pulisher
Feb 28, 2025

Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia

Feb 27, 2025
pulisher
Feb 26, 2025

Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Jan 31, 2025

StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World

Jan 31, 2025
pulisher
Dec 05, 2024

Galmed Phar stock hits 52-week low at $2.6 amid market challenges - Investing.com Nigeria

Dec 05, 2024
pulisher
Dec 05, 2024

Galmed Phar stock hits 52-week low at $2.6 amid market challenges By Investing.com - Investing.com South Africa

Dec 05, 2024
pulisher
Nov 26, 2024

Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa

Nov 26, 2024
pulisher
Nov 26, 2024

Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria

Nov 26, 2024
pulisher
Nov 16, 2024

Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register

Nov 16, 2024

Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
Cap:     |  Volume (24h):